Educational only — not medical advice.If you’re in crisis or thinking about suicide: call or text 988 (U.S.) or your local emergency number. Support resources.Under construction and review—see the updates log.
Common US brands: INVEGA SUSTENNA, INVEGA TRINZA, INVEGA HAFYERA
Typical dose range: PP1M initiation uses a labeled loading sequence (deltoid injections on day 1 and day 8) followed by monthly maintenance. Oral overlap is not typically required after the loading sequence.
Long-acting injectable formulation available.
Therapeutic drug monitoring not routinely recommended.
Last reviewed: 2025-12-30
Dosing & forms
Forms/strengths: PP1M: intramuscular injection monthly after labeled loading sequence.; PP3M: intramuscular injection every 3 months after stabilization.; PP6M: intramuscular injection every 6 months after stabilization.
Frequency: PP1M initiation uses a labeled loading sequence (deltoid injections on day 1 and day 8) followed by monthly maintenance. Oral overlap is not typically required after the loading sequence.
Typical range: PP1M initiation uses a labeled loading sequence (deltoid injections on day 1 and day 8) followed by monthly maintenance. Oral overlap is not typically required after the loading sequence.
Mechanism (brief)
Long-acting injectable prodrug of paliperidone (D2 and 5-HT2A antagonist; active metabolite of risperidone) used for maintenance treatment with monthly, 3-month, or 6-month dosing intervals depending on formulation.